Slide show: Wheeling and dealing at J.P. Morgan 2012

Launch slide show >>

FierceBiotech's news team met with a number of drug developers this week at the J.P. Morgan Healthcare Conference in San Francisco, and wanted to put our readers up close to the action. So, in addition to our laptops, we toted cameras into our meetings with company chiefs (OK, most of us snapped photos with our smartphones). This slide show gives you a quick take on the status of each of the companies and pictures of the leaders as they looked on very little sleep and, in many cases, after too many meetings to count. Launch slide show >>

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.